SBFM Q3 2023 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$6M+4386.2% YoY

Gross Profit

$2M33.4% margin

Operating Income

-$779,000-13.1% margin

Net Income

-$651,000-10.9% margin

EPS (Diluted)

$-50.72

QoQ Revenue Growth

+7.1%

Cash Flow

Operating Cash Flow

-$457,289

Free Cash Flow

-$469,082

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$28M

Total Liabilities

$6M

Stockholders' Equity

$22M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$132,808	+4386.2%
Gross Profit	$2M	$67,025	+2869.0%
Operating Income	-$779,000	-$2M	+54.7%
Net Income	-$651,000	-$1M	+55.3%